Brief Summary:
This study is intended to investigate safety and feasibility of a new weight loss technique called endoscopic Gastric Mucosal Ablation (GMA) that does not require surgery, but can be achieved using an endoscopic procedure.
Previous studies have suggested that weight loss after vertical sleeve gastrectomy (VSG) is partly due to the removal of normal stomach tissue suspected of having hormonal function. The study will investigate the minimally invasive treatment of obesity by means of argon plasma coagulation (APC) in combination with waterjet submucosal injection using HybridAPC.
As primary objective total body weight loss (TBWL) will be determined as body weight difference at the 6 months follow up (FU) visit after the last treatment session in comparison to the body weight prior to the initial treatment.
After signing the informed consent the doctor and research team will determine if the participant meets all requirements for this study. If a participant is confirmed to be a suitable candidate additional tests will be performed prior to the first application of GMA to assess the health status of the participant prior to treatment. During the screening and baseline visit the medical history and the medications of the participant will be reviewed.
After the treatments the participants will be followed for up to 12 months to assess the outcome of the GMA procedure.
傳統縮胃相關的手術(內視鏡袖狀縮胃、縮胃曠腸、縮胃繞道等)，在縮胃的過程中會切去大多數的胃部，使得胃部相關的激素，尤其是大家不喜歡的飢餓素，大量伴隨被切除的胃部而從身體中消失，使得接受術式後可以伴隨飢餓感的下降。
Endoscopic Gastric Mucosal Ablation as a Primary Obesity Therapy (COMET) 內視鏡胃黏膜燒灼術
使用胃鏡與Argon雷射去做胃部黏膜的燒灼，如何能達到減重的效果呢?
一次性取得胃部縮小與飢餓素下降的原理
經由雷射去對胃部的黏膜做人造傷害，可以讓胃黏膜在受損後出現疤痕組織，原本柔軟的胃黏膜，就會變成比較有韌性的疤痕組織，胃部擴張的範圍就會受限，取得一個胃部容量下降的功能，經由破壞黏膜以及黏膜下組織，去減少飢餓素的感受，甚至破壞飢餓素，達到下降飢餓素影響我們身體的需求。
最終研究結果預計於: 2025年9月發表
